Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate r...
Saved in:
| Published in: | Genome medicine Vol. 13; no. 1; pp. 107 - 11 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
23.06.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1756-994X, 1756-994X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required. |
|---|---|
| AbstractList | Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required. Keywords: Intestinal microbiome, Metabolites, Immune checkpoint inhibitors Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required.Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required. Abstract Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required. |
| ArticleNumber | 107 |
| Audience | Academic |
| Author | Jenq, Robert R. Hayase, Eiko |
| Author_xml | – sequence: 1 givenname: Eiko surname: Hayase fullname: Hayase, Eiko organization: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center – sequence: 2 givenname: Robert R. orcidid: 0000-0002-5434-439X surname: Jenq fullname: Jenq, Robert R. email: RRJenq@mdanderson.org organization: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, CPRIT Scholar in Cancer Research |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34162429$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltr3DAQhU1JaS7tH-hDMRRCX5zKsizJL4UQegkECqWFvglZGu9qI0tb2U7Iv-9snG12Qwl-kD0655M1c46zgxADZNnbkpyVpeQfh7IioioILQtCGloVty-yo1LUvGga9vtg5_0wOx6GFSGcUSZeZYcVKzlltDnK7n5ED3ns8nEJuQsjDKML2ue9Mym2LvaQ62C3n9oXFpK7AazAqNvoHTrQl7u-nwLkZgnmeh0RlLc-mmttYd6KyE96fbc5yuhgIL3OXnbaD_DmYT3Jfn35_PPiW3H1_evlxflVYXglx6Iz1FJhK7CgbWd0yyTUUgpRtwSsrphtoeRtBwwsIcA5NYYxwAYxK6wk1Ul2OXNt1Cu1Tq7X6U5F7dR9IaaF0ml0xoMCLcG2NRdM1swYKistSl5abUkt68Yg69PMWk9tD9ZAGJP2e9D9neCWahFvlKSUCMoR8OEBkOKfCZutejcY8F4HiNOgaM2YFA2VAqXvn0hXcUo4m42qrmiJw6weVQuNF3Chi3iu2UDVOReUckyGRNXZf1T4WMDJYqo6h_U9w-mOYQnaj8sh-ml0MQz7wne7HfnXim3CUCBnAQZoGBJ0yrhRbzj4C86rkqhNmNUcZoVhVvdhVrdopU-sW_qzpmo2DSgOC0iPbXvG9Rdi5AkG |
| CitedBy_id | crossref_primary_10_3389_fnut_2022_867692 crossref_primary_10_1016_j_bcp_2022_114916 crossref_primary_10_3389_fimmu_2024_1411490 crossref_primary_10_3390_cancers15143708 crossref_primary_10_1080_02648725_2023_2212526 crossref_primary_10_1111_jcmm_18470 crossref_primary_10_1136_jitc_2023_008686 crossref_primary_10_1016_j_semcancer_2025_06_009 crossref_primary_10_3389_fonc_2021_763027 crossref_primary_10_3390_ijms23179834 crossref_primary_10_1016_j_compbiolchem_2025_108372 crossref_primary_10_1134_S0006297923070027 crossref_primary_10_1016_j_semcancer_2025_06_012 crossref_primary_10_1038_s41467_024_54565_8 crossref_primary_10_3748_wjg_v29_i9_1395 crossref_primary_10_3390_microorganisms11051240 crossref_primary_10_1038_s41467_024_55388_3 crossref_primary_10_1038_s41568_022_00529_3 crossref_primary_10_3390_microorganisms12112256 crossref_primary_10_1038_s41392_023_01619_w crossref_primary_10_1007_s00262_024_03665_x crossref_primary_10_3389_fonc_2021_803133 crossref_primary_10_1084_jem_20220948 crossref_primary_10_3390_pharmaceutics15082138 crossref_primary_10_3389_fcimb_2022_953718 crossref_primary_10_1136_jitc_2024_010419 crossref_primary_10_1016_j_critrevonc_2022_103757 crossref_primary_10_3389_fmed_2022_875974 crossref_primary_10_1007_s00774_023_01404_3 crossref_primary_10_1016_j_critrevonc_2024_104405 crossref_primary_10_1016_j_jare_2025_08_038 crossref_primary_10_1097_MOG_0000000000000892 crossref_primary_10_3389_fonc_2024_1402483 crossref_primary_10_1080_08830185_2024_2312294 crossref_primary_10_1038_s41392_023_01653_8 crossref_primary_10_3389_fimmu_2024_1444589 crossref_primary_10_1016_j_jconrel_2025_02_072 crossref_primary_10_1186_s12865_025_00710_x crossref_primary_10_1007_s11255_023_03760_5 crossref_primary_10_1016_j_jconrel_2024_04_043 crossref_primary_10_3390_ijms241411855 crossref_primary_10_3389_fimmu_2021_807648 crossref_primary_10_1155_2022_9315283 crossref_primary_10_3389_fgene_2022_1069780 crossref_primary_10_3390_cancers15184426 crossref_primary_10_1080_17474124_2022_2064273 crossref_primary_10_1016_j_hbpd_2022_08_002 crossref_primary_10_3389_fimmu_2022_899161 crossref_primary_10_1016_j_chom_2024_10_006 crossref_primary_10_1080_2162402X_2022_2064958 crossref_primary_10_1016_j_lfs_2022_121138 crossref_primary_10_3390_ijms26031066 crossref_primary_10_3389_fonc_2022_871513 crossref_primary_10_1186_s40364_024_00607_8 crossref_primary_10_3390_ijms24032769 crossref_primary_10_4103_jcrt_jcrt_41_24 crossref_primary_10_2217_imt_2022_0250 crossref_primary_10_3390_cancers14215369 crossref_primary_10_1097_CM9_0000000000003687 crossref_primary_10_1016_j_drudis_2023_103797 crossref_primary_10_1007_s11864_022_01027_2 crossref_primary_10_3389_fcimb_2021_673724 crossref_primary_10_3390_molecules27154799 crossref_primary_10_3389_fmolb_2023_1140325 crossref_primary_10_1016_j_ccell_2021_08_006 crossref_primary_10_1155_2022_6069403 crossref_primary_10_3389_fimmu_2022_915047 crossref_primary_10_1021_acsami_5c02939 crossref_primary_10_3389_fimmu_2024_1368749 crossref_primary_10_1186_s12967_024_05552_6 crossref_primary_10_1080_10408398_2022_2094888 crossref_primary_10_1177_20503121241274724 crossref_primary_10_1007_s12032_023_02006_9 crossref_primary_10_1007_s12094_024_03615_0 crossref_primary_10_3389_fimmu_2024_1403533 crossref_primary_10_3389_fgene_2021_785153 crossref_primary_10_2217_imt_2022_0245 crossref_primary_10_1016_j_lungcan_2023_107347 crossref_primary_10_1097_CM9_0000000000003430 crossref_primary_10_5306_wjco_v13_i6_448 crossref_primary_10_1007_s00262_025_04018_y crossref_primary_10_3390_cancers15010263 crossref_primary_10_1007_s12016_023_08958_0 crossref_primary_10_1111_imm_13785 crossref_primary_10_1039_D3FO02110F crossref_primary_10_3390_ijms231810617 crossref_primary_10_1186_s12967_023_04338_6 crossref_primary_10_3389_fimmu_2022_952546 crossref_primary_10_3389_fmicb_2024_1328324 crossref_primary_10_1515_oncologie_2023_0511 crossref_primary_10_3390_cancers16010133 |
| Cites_doi | 10.1038/nrc3153 10.1038/s41576-019-0127-1 10.1126/science.aao3290 10.1126/science.abb5920 10.1177/1756284819870911 10.1172/jci.insight.93397 10.1016/j.immuni.2016.09.009 10.1056/NEJMoa1200694 10.1038/s41571-019-0218-0 10.21037/tlcr-20-380 10.1073/pnas.1712901115 10.1038/nrgastro.2011.244 10.1126/science.1240537 10.1245/s10434-009-0585-3 10.1080/2162402X.2018.1507670 10.21037/jtd-20-1953 10.1126/science.aax0701 10.1038/s41586-019-1922-8 10.1056/NEJMoa1504030 10.1056/NEJMoa020177 10.1038/s41467-019-12361-9 10.1126/science.1240527 10.1126/science.aac4255 10.1038/s41575-019-0258-z 10.1172/jci.insight.135597 10.1136/gutjnl-2020-323426 10.1093/annonc/mdx108 10.1038/nature13988 10.1001/jamanetworkopen.2020.2895 10.1038/s41586-019-1593-5 10.1126/science.1223490 10.1126/science.aad1329 10.1080/2162402X.2015.1132137 10.1093/annonc/mdy103 10.1016/j.chom.2012.09.009 10.1126/science.abf3363 10.1093/annonc/mdv623 10.1126/science.abc3421 10.1007/s12094-020-02421-8 10.1111/imr.12563 10.1186/s12967-020-02231-0 10.1056/NEJMoa1411087 10.1146/annurev-pathmechdis-012418-012818 10.1038/s41591-018-0238-9 10.1016/j.ijid.2021.03.063 10.1038/ncomms10391 10.1186/s40425-019-0699-5 10.1038/s41423-020-00565-9 10.1056/NEJMoa1003466 10.1016/j.cell.2017.04.004 10.1200/JCO.19.00320 10.1038/nm.4511 10.1038/nrc.2017.13 10.1007/s12282-020-01084-1 10.2217/fon-2020-0215 10.1038/s41467-018-05470-4 10.1056/NEJMoa1205037 10.1038/nm.4051 10.1016/j.ccell.2020.10.001 10.1038/nbt.3960 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 10.1126/science.aan4236 10.1126/science.aan3706 10.1038/s41586-020-2095-1 10.1038/s41586-019-0878-z 10.1080/2162402X.2019.1568812 10.1038/s41467-020-16079-x 10.1001/jamaoncol.2019.2785 10.1056/NEJMoa1302369 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13073-021-00923-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1756-994X |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_ea8edb5674854cc283a7161dad05859c PMC8220726 A672260098 34162429 10_1186_s13073_021_00923_w |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Cancer Prevention and Research Institute of Texas (US) grantid: RR160089 – fundername: Foundation for the National Institutes of Health grantid: R01HL124112 and P30CA016672 funderid: http://dx.doi.org/10.13039/100000009 – fundername: NHLBI NIH HHS grantid: R01 HL124112 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: ; grantid: R01HL124112 and P30CA016672 – fundername: ; grantid: RR160089 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACJQM ACUHS ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIAM BBNVY BENPR BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 LK8 M1P M7P MK0 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ TUS UKHRP AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-fc2d27d3edeadfcab48e588775b0eda34dbe16bfe4ed00e662cc44e1184d7d803 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 111 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000664995500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-994X |
| IngestDate | Fri Oct 03 12:50:26 EDT 2025 Tue Nov 04 01:56:03 EST 2025 Fri Sep 05 06:29:46 EDT 2025 Tue Oct 14 12:41:52 EDT 2025 Tue Nov 11 10:28:23 EST 2025 Tue Nov 04 17:34:35 EST 2025 Thu May 22 21:21:49 EDT 2025 Mon Jul 21 06:07:14 EDT 2025 Sat Nov 29 06:05:13 EST 2025 Tue Nov 18 21:40:40 EST 2025 Sat Sep 06 07:28:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Metabolites Intestinal microbiome Immune checkpoint inhibitors |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-fc2d27d3edeadfcab48e588775b0eda34dbe16bfe4ed00e662cc44e1184d7d803 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5434-439X |
| OpenAccessLink | https://doaj.org/article/ea8edb5674854cc283a7161dad05859c |
| PMID | 34162429 |
| PQID | 2553216423 |
| PQPubID | 2040231 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ea8edb5674854cc283a7161dad05859c pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220726 proquest_miscellaneous_2544879287 proquest_journals_2553216423 gale_infotracmisc_A672260098 gale_infotracacademiconefile_A672260098 gale_healthsolutions_A672260098 pubmed_primary_34162429 crossref_citationtrail_10_1186_s13073_021_00923_w crossref_primary_10_1186_s13073_021_00923_w springer_journals_10_1186_s13073_021_00923_w |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-23 |
| PublicationDateYYYYMMDD | 2021-06-23 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Genome medicine |
| PublicationTitleAbbrev | Genome Med |
| PublicationTitleAlternate | Genome Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | D Donnelly (923_CR36) 2019; 7 N Chaput (923_CR12) 2017; 28 G Lamberti (923_CR37) 2020; 16 O Demaria (923_CR64) 2019; 574 A Fluckiger (923_CR69) 2020; 369 II Ivanov (923_CR15) 2012; 12 C Coutzac (923_CR50) 2020; 11 K Dubin (923_CR59) 2016; 7 S Ogino (923_CR34) 2019; 14 J Larkin (923_CR6) 2015; 373 DL Jardim (923_CR9) 2021; 39 JR Brahmer (923_CR3) 2012; 366 MD Buck (923_CR46) 2017; 169 HM Roager (923_CR51) 2018; 9 M Karayama (923_CR53) 2021; 23 T Tanoue (923_CR29) 2019; 565 V Gopalakrishnan (923_CR26) 2018; 359 P Sharma (923_CR4) 2011; 11 M Nomura (923_CR48) 2020; 3 R Daillere (923_CR18) 2016; 45 H Abu-Sbeih (923_CR57) 2019; 37 F Kocher (923_CR55) 2021; 10 CL Sears (923_CR13) 2018; 24 N Iida (923_CR17) 2013; 342 923_CR66 923_CR63 923_CR65 S Roy (923_CR23) 2017; 17 D Davar (923_CR39) 2021; 371 LF Mager (923_CR54) 2020; 369 V Tam (923_CR33) 2019; 20 A Lavelle (923_CR47) 2020; 17 LV Hooper (923_CR14) 2012; 336 M Vetizou (923_CR24) 2015; 350 DJ Pinato (923_CR41) 2019; 5 FS Hodi (923_CR1) 2010; 363 E van Nood (923_CR61) 2013; 368 DL Chen (923_CR35) 2021; 13 A Botticelli (923_CR49) 2020; 18 A Sivan (923_CR25) 2015; 350 923_CR10 L Derosa (923_CR40) 2018; 29 T Jamiyan (923_CR22) 2020; 27 A Gros (923_CR68) 2016; 22 EN Baruch (923_CR38) 2021; 371 S Kim (923_CR43) 2017; 279 H Li (923_CR52) 2019; 10 L Zhang (923_CR20) 2003; 348 CG Clemente (923_CR19) 1996; 77 GD Poore (923_CR32) 2020; 579 PI Costea (923_CR31) 2017; 35 B Routy (923_CR27) 2018; 359 JD Wolchok (923_CR2) 2013; 369 BA Helmink (923_CR30) 2020; 577 TJ Borody (923_CR60) 2011; 9 JM Pitt (923_CR11) 2017; 6 SC Katz (923_CR21) 2009; 16 J Ahmed (923_CR44) 2018; 7 S Champiat (923_CR7) 2016; 27 M Tsikala-Vafea (923_CR45) 2021; 106 RC Pezo (923_CR56) 2019; 12 Y Wang (923_CR62) 2018; 24 SM Ansell (923_CR5) 2015; 372 S Viaud (923_CR16) 2013; 342 F Wang (923_CR58) 2018; 115 V Matson (923_CR28) 2018; 359 F Martins (923_CR8) 2019; 16 A Elkrief (923_CR42) 2019; 8 MM Gubin (923_CR67) 2014; 515 |
| References_xml | – volume: 11 start-page: 805 issue: 11 year: 2011 ident: 923_CR4 publication-title: Nat Rev Cancer doi: 10.1038/nrc3153 – volume: 20 start-page: 467 issue: 8 year: 2019 ident: 923_CR33 publication-title: Nat Rev Genet doi: 10.1038/s41576-019-0127-1 – volume: 359 start-page: 104 issue: 6371 year: 2018 ident: 923_CR28 publication-title: Science doi: 10.1126/science.aao3290 – volume: 371 start-page: 602 issue: 6529 year: 2021 ident: 923_CR38 publication-title: Science doi: 10.1126/science.abb5920 – volume: 12 start-page: 175628481987091 year: 2019 ident: 923_CR56 publication-title: Ther Adv Gastroenterol doi: 10.1177/1756284819870911 – ident: 923_CR65 doi: 10.1172/jci.insight.93397 – volume: 45 start-page: 931 issue: 4 year: 2016 ident: 923_CR18 publication-title: Immunity doi: 10.1016/j.immuni.2016.09.009 – volume: 366 start-page: 2455 issue: 26 year: 2012 ident: 923_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 – volume: 16 start-page: 563 issue: 9 year: 2019 ident: 923_CR8 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0218-0 – volume: 10 start-page: 304 issue: 1 year: 2021 ident: 923_CR55 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-20-380 – volume: 115 start-page: 157 issue: 1 year: 2018 ident: 923_CR58 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1712901115 – volume: 9 start-page: 88 issue: 2 year: 2011 ident: 923_CR60 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2011.244 – volume: 342 start-page: 971 issue: 6161 year: 2013 ident: 923_CR16 publication-title: Science doi: 10.1126/science.1240537 – volume: 16 start-page: 2524 issue: 9 year: 2009 ident: 923_CR21 publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0585-3 – volume: 7 issue: 11 year: 2018 ident: 923_CR44 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1507670 – volume: 13 start-page: 220 issue: 1 year: 2021 ident: 923_CR35 publication-title: J Thorac Dis doi: 10.21037/jtd-20-1953 – volume: 369 start-page: 936 issue: 6506 year: 2020 ident: 923_CR69 publication-title: Science doi: 10.1126/science.aax0701 – volume: 577 start-page: 549 issue: 7791 year: 2020 ident: 923_CR30 publication-title: Nature doi: 10.1038/s41586-019-1922-8 – volume: 373 start-page: 23 issue: 1 year: 2015 ident: 923_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504030 – volume: 348 start-page: 203 issue: 3 year: 2003 ident: 923_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa020177 – volume: 10 start-page: 4346 issue: 1 year: 2019 ident: 923_CR52 publication-title: Nat Commun doi: 10.1038/s41467-019-12361-9 – volume: 342 start-page: 967 issue: 6161 year: 2013 ident: 923_CR17 publication-title: Science doi: 10.1126/science.1240527 – volume: 350 start-page: 1084 issue: 6264 year: 2015 ident: 923_CR25 publication-title: Science doi: 10.1126/science.aac4255 – volume: 17 start-page: 223 issue: 4 year: 2020 ident: 923_CR47 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-019-0258-z – ident: 923_CR63 doi: 10.1172/jci.insight.135597 – ident: 923_CR66 doi: 10.1136/gutjnl-2020-323426 – volume: 28 start-page: 1368 issue: 6 year: 2017 ident: 923_CR12 publication-title: Ann Oncol doi: 10.1093/annonc/mdx108 – volume: 515 start-page: 577 issue: 7528 year: 2014 ident: 923_CR67 publication-title: Nature doi: 10.1038/nature13988 – volume: 3 issue: 4 year: 2020 ident: 923_CR48 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.2895 – volume: 574 start-page: 45 issue: 7776 year: 2019 ident: 923_CR64 publication-title: Nature doi: 10.1038/s41586-019-1593-5 – volume: 336 start-page: 1268 issue: 6086 year: 2012 ident: 923_CR14 publication-title: Science doi: 10.1126/science.1223490 – volume: 350 start-page: 1079 issue: 6264 year: 2015 ident: 923_CR24 publication-title: Science doi: 10.1126/science.aad1329 – volume: 6 issue: 1 year: 2017 ident: 923_CR11 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1132137 – volume: 29 start-page: 1437 issue: 6 year: 2018 ident: 923_CR40 publication-title: Ann Oncol doi: 10.1093/annonc/mdy103 – volume: 12 start-page: 496 issue: 4 year: 2012 ident: 923_CR15 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2012.09.009 – volume: 371 start-page: 595 issue: 6529 year: 2021 ident: 923_CR39 publication-title: Science doi: 10.1126/science.abf3363 – volume: 27 start-page: 559 issue: 4 year: 2016 ident: 923_CR7 publication-title: Ann Oncol doi: 10.1093/annonc/mdv623 – volume: 369 start-page: 1481 issue: 6510 year: 2020 ident: 923_CR54 publication-title: Science doi: 10.1126/science.abc3421 – volume: 23 start-page: 418 issue: 2 year: 2021 ident: 923_CR53 publication-title: Clin Transl Oncol doi: 10.1007/s12094-020-02421-8 – volume: 279 start-page: 90 issue: 1 year: 2017 ident: 923_CR43 publication-title: Immunol Rev doi: 10.1111/imr.12563 – volume: 18 start-page: 49 issue: 1 year: 2020 ident: 923_CR49 publication-title: J Transl Med doi: 10.1186/s12967-020-02231-0 – volume: 372 start-page: 311 issue: 4 year: 2015 ident: 923_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa1411087 – volume: 14 start-page: 83 issue: 1 year: 2019 ident: 923_CR34 publication-title: Annu Rev Pathol doi: 10.1146/annurev-pathmechdis-012418-012818 – volume: 24 start-page: 1804 issue: 12 year: 2018 ident: 923_CR62 publication-title: Nat Med doi: 10.1038/s41591-018-0238-9 – volume: 106 start-page: 142 year: 2021 ident: 923_CR45 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.03.063 – volume: 7 start-page: 10391 issue: 1 year: 2016 ident: 923_CR59 publication-title: Nat Commun doi: 10.1038/ncomms10391 – volume: 7 start-page: 222 issue: 1 year: 2019 ident: 923_CR36 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0699-5 – ident: 923_CR10 doi: 10.1038/s41423-020-00565-9 – volume: 363 start-page: 711 issue: 8 year: 2010 ident: 923_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 169 start-page: 570 issue: 4 year: 2017 ident: 923_CR46 publication-title: Cell doi: 10.1016/j.cell.2017.04.004 – volume: 37 start-page: 2738 issue: 30 year: 2019 ident: 923_CR57 publication-title: J Clin Oncol doi: 10.1200/JCO.19.00320 – volume: 24 start-page: 254 issue: 3 year: 2018 ident: 923_CR13 publication-title: Nat Med doi: 10.1038/nm.4511 – volume: 17 start-page: 271 issue: 5 year: 2017 ident: 923_CR23 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.13 – volume: 27 start-page: 880 issue: 5 year: 2020 ident: 923_CR22 publication-title: Breast Cancer doi: 10.1007/s12282-020-01084-1 – volume: 16 start-page: 1751 issue: 23 year: 2020 ident: 923_CR37 publication-title: Future Oncol doi: 10.2217/fon-2020-0215 – volume: 9 start-page: 3294 issue: 1 year: 2018 ident: 923_CR51 publication-title: Nat Commun doi: 10.1038/s41467-018-05470-4 – volume: 368 start-page: 407 issue: 5 year: 2013 ident: 923_CR61 publication-title: N Engl J Med doi: 10.1056/NEJMoa1205037 – volume: 22 start-page: 433 issue: 4 year: 2016 ident: 923_CR68 publication-title: Nat Med doi: 10.1038/nm.4051 – volume: 39 start-page: 154 issue: 2 year: 2021 ident: 923_CR9 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.10.001 – volume: 35 start-page: 1069 issue: 11 year: 2017 ident: 923_CR31 publication-title: Nat Biotechnol doi: 10.1038/nbt.3960 – volume: 77 start-page: 1303 issue: 7 year: 1996 ident: 923_CR19 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 – volume: 359 start-page: 97 issue: 6371 year: 2018 ident: 923_CR26 publication-title: Science doi: 10.1126/science.aan4236 – volume: 359 start-page: 91 issue: 6371 year: 2018 ident: 923_CR27 publication-title: Science doi: 10.1126/science.aan3706 – volume: 579 start-page: 567 issue: 7800 year: 2020 ident: 923_CR32 publication-title: Nature doi: 10.1038/s41586-020-2095-1 – volume: 565 start-page: 600 issue: 7741 year: 2019 ident: 923_CR29 publication-title: Nature doi: 10.1038/s41586-019-0878-z – volume: 8 issue: 4 year: 2019 ident: 923_CR42 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1568812 – volume: 11 start-page: 2168 issue: 1 year: 2020 ident: 923_CR50 publication-title: Nat Commun doi: 10.1038/s41467-020-16079-x – volume: 5 start-page: 1774 issue: 12 year: 2019 ident: 923_CR41 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.2785 – volume: 369 start-page: 122 issue: 2 year: 2013 ident: 923_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa1302369 |
| SSID | ssj0064247 |
| Score | 2.5710099 |
| SecondaryResourceType | review_article |
| Snippet | Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune... Abstract Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 107 |
| SubjectTerms | Anti-Bacterial Agents - pharmacology Antibiotics Antibodies Antigen (tumor-associated) Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B cells Bacteria Bioinformatics Biomarkers Biomedical and Life Sciences Biomedicine Cancer Cancer immunotherapy Cancer Research Cancer therapies Care and treatment Chemotherapy Colitis Colitis - etiology Cytotoxicity Development and progression Drug therapy Dysbiosis - etiology Epitopes Fecal microflora Gastrointestinal Microbiome - drug effects Gastrointestinal Microbiome - immunology Gene expression Host Microbial Interactions - drug effects Host Microbial Interactions - immunology Human Genetics Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immune response Immune response (cell-mediated) Immune system Immunomodulation Immunotherapy Inflammatory bowel disease Intestinal microbiome Intestine Lymphocytes Lymphocytes T Medical research Medicine/Public Health Melanoma Metabolites Metabolome - drug effects Metabolomics Metabolomics - methods Microbiomes Microbiota Microbiota (Symbiotic organisms) Models, Biological Monoclonal antibodies Neoplasms - complications Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Obesity Oncology, Experimental Oral administration Patients Review Systems Biology T cells Translating the microbiome in health and disease Transplantation Tumor antigens Tumor microenvironment Tumors |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED_BAImX8c0CA4KExANESx3HTp7QQEw8TRMCaW-WY1-hWpeUttvU_54752NkiL3w2Pjc1r7fne-c-wB4o9AWKvVFgkJN-bZKJ2SFkLinE2_TEgsaC80m9OFhcXxcHnUXbqsurLLXiUFR-8bxHfkemb6ZINteZB8WvxLuGsVvV7sWGjfhFldJyELo3lGviYlY6j5RplB7qwkDOuGgBC41lCUXo8Mo1Oz_WzP_cTRdDZu88u40HEkH9_53MfdhuzNG4_0WPQ_gBtYP4U7bnnLzCDZfmznGzTQmIzHmuhKkDpj-dNZWbzrF2Na-_2jniSc4nyM9wTVhi7ObVzQvnnEOCsYED3eyaOiL4oqO0BPrsR3qksA2_FOOUbh8DN8PPn_79CXpWjUkjgR4nUyd8EL7DD0hc-psJQvMSX_pvErR20z6CieqmqJEn6aolHBOSiS2SK99kWZPYKtuatyBOHdZ6oXwZDxIqW1ZlbrKS2m9y73KJUYw6XlmXFfHnNtpzE3wZwplWj4b4rMJfDYXEbwb5izaKh7XUn9kKAyUXIE7PGiWP0wn0IYwjr7KuVdLLp0jK82S60kA9yl5YKWL4BUDybTprIMeMftKC24KUBYRvA0UrEloAc52CRG0DVyTa0S5O6IkDeDGwz3KTKeBVuYSYhG8HoZ5JkfV1dicMQ0557okpzmCpy22h0WTdcOpQ2UEeoT60a6MR-rZz1CfnGzOVAsVwftePi7_1r93_dn1q3gOd0WQXJWIbBe21sszfAG33fl6tlq-DHL_G0FbYWQ priority: 102 providerName: ProQuest – databaseName: Springer Journals New Starts & Take-Overs Collection dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5BAYkX7iNQIEhIPEBE1nHs5LEgKp4qVA71zXLsSVl1m1S721b775lxDkg5JHjczDi7nnxzbTwzAC8U2kKlvkhQqJr_rdIJRSGk7unM27TEgmhh2ITe2ysODsqPfVHYajjtPrySDJY6qHWh3qxmDMeEjxRwo6AsOb8MV8jdFayO-5--DvaXAmqph_KY366buKDQqf9Xe_yTQ7p4WPLCG9PgiHZv_t8WbsGNPvCMdzqk3IZL2NyBa90oys1d2Oy3C4zbOqaAMOYeEqT6zH887zo1HWNsGz98tIvEE3TPkK7gmnDElcwrWhfPud4EY4KCOzpp6UZxRe7yyHrsSH3B14a_yjHilvfgy-77z-8-JP1YhsSRsq6T2gkvtM_QEwprZytZYE62SudVit5m0lc4U1WNEn2aolLCOSmRJCC99kWa3Yetpm3wIcS5y1IvhKdAQUpty6rUVV5K613uVS4xgtnwpIzre5bz6IyFCblLoUwnUkMiNUGk5jyCV-Oak65jx1-53zIARk7uth0utMtD0yuvITyjr3Key5JL5ygis5RmEph9StlW6SJ4xvAxXenqaDPMjtKCBwCURQQvAwdbDdqAs33xA4mB-29NOLcnnKTtbkoeIGp6a7MylBZmgvJekUXwfCTzSj5B12B7yjyUiOuSEuQIHnSIHjdNkQyXCZUR6AnWJ1KZUpr5t9CLnOLLVAsVwesB8T9-1p-l_ujf2B_DdRGURiUi24at9fIUn8BVd7aer5ZPg_Z_ByD3WEA priority: 102 providerName: Springer Nature |
| Title | Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer |
| URI | https://link.springer.com/article/10.1186/s13073-021-00923-w https://www.ncbi.nlm.nih.gov/pubmed/34162429 https://www.proquest.com/docview/2553216423 https://www.proquest.com/docview/2544879287 https://pubmed.ncbi.nlm.nih.gov/PMC8220726 https://doaj.org/article/ea8edb5674854cc283a7161dad05859c |
| Volume | 13 |
| WOSCitedRecordID | wos000664995500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RBZ dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M7P dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RSV dateStart: 20090101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdggMQL4pvAKEFC4gGipY5jJ48b2gQPVFX5UHmyHPuqVeuSqe029b_nzk7KMgS88FIp8dlNzr_7an13jL2RYAqZuiIBLmf0a5VK0AtBcU-HzqQlFDjmm02o0aiYTsvxlVZfdCYslAcOjNvDtcBVOfXEyIW1aA0Nuvi4kEvR0y0taV_0erpgKuhgdKqF6lJkCrm3GhKUEzqOQEWGsuSyZ4Z8tf7fdfIVo3T9wOS1f029MTq6z-61XmS8H57-AbsB9UN2J_SV3Dxim0mzgLiZxejdxVQQAuWY6E_noezSKcSmdt2lWSQOcXgBeAfWCApKS17hvHhOySMQ477ak7MGF4ortH0nxkEYarO3NvRVluCzfMy-HR1-_fAxaXssJBYlb53MLHdcuQwcQmpmTSUKyFHxqLxKwZlMuAqGspqBAJemICW3VghArgqnXJFmT9hO3dTwjMW5zVLHuUOrL4QyZVWqKi-FcTZ3MhcQsWHHcm3bAuTUB2OhfSBSSB22SeM2ab9N-jJi77ZzzkL5jb9SH9BObimpdLa_gYDSLaD0vwAVsVeEAx3yULcKQO9Lxamaf1lE7K2nIBWAL2BNm8mAbKBiWj3K3R4liq7tD3dY063qWGmM8TKOQSzPIvZ6O0wz6ThcDc050WBUrUqMdiP2NEBz-9LollDOTxkx1QNtjyv9kXp-7AuLo7OYKi4j9r6D96_H-jPXn_8Prr9gd7kXT5nwbJftrJfn8JLdthfr-Wo5YDfVVPnPYsBuHRyOxpOBF_gBndUd473xp8_jH3g1-fL9J_ahWro |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL70eg0CCBOJSoWcdxkgNC5VG1aqkqVKTeTGLPwqrbZNnddrV_it_IjJNsSRG99cBx40k2dub7_DnxzAC8VJinKrRpgEL1-W1VEpAKIbiHPZuHGabU5opNJHt76eFhtr8Ev9pYGN5W2XKiI2pbGX5Hvk7SNxKk7UX0bvQz4KpR_HW1LaFRu8UOzme0ZJu83f5Iz_eVEJufDj5sBU1VgcCQr02DvhFWJDZCS4PYN3khU4wJaklchGjzSNoCe6roo0QbhqiUMEZKJCEubWLTMKLrXoGrJCNE6rYK7rfMTzcnkzYwJ1Xrkx4DKOBNEJzaKApmncnP1Qj4eyb4Yyo8v03z3LdaNwVu3v7fBu8O3GrEtr9Ro-MuLGF5D67X5Tfn92H-pRqiX_V9EsE-580gumP740GdneoY_by07c98GFiC6ynSEZwSdjh6e0Ln-QOOsUGf3N8cjSq6kF-QRDjKLdZNTZDbnP_KMMrGD-DrpfT7ISyXVYmPwY9NFFohLIkjKZM8K7KkiDOZWxNbFUv0oNf6iDZNnnYuFzLUbr2WKl37lSa_0s6v9MyDtcU5ozpLyYXW79n1FpacYdwdqMbfdUNYmjCMtoi5Fk0sjSEVmtPSmgBsQ1phZsaDVXZcXYfrLnhSb6hEcNGDLPXgtbNgpqQOmLwJ-KBh4JxjHcuVjiUxnOk2t16tG4ad6DOX9uDFopnP5F2DJVYnbCNpPZ6JNPHgUY2lRadJvXFoVOZB0kFZZ1S6LeXgh8u_Tpo6TITy4E2Lx7Pb-veoP7m4F6twY-vg867e3d7beQo3hWMNFYhoBZan4xN8BtfM6XQwGT93nOPDt8vG6W9rqcKH |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9NAEB5BOcQL92Eo1EhIPFCrznq9az-WowKBoopLfVutd8cQNbWjJG2Vf8-Mj1CXQ0I8xjvrZMffzM7EO98APFNoMxX7LEKhSv63SkcUhZC5xyNv4xwzGmuaTejxODs4yPfPVPE3p937V5JtTQOzNFXLnZkvWxPP1M5ixNCM-HgBkwYl0elFuCS5aRDn65--9r6Ygmup-1KZ384bbEcNa_-vvvnM5nT-4OS5t6fNprR34_-XcxOudwFpuNsi6BZcwOo2XGlbVK7uwOpjPcWwLkMKFEPmliCXwPJHk5bB6QhDW_n-o51GniB9gnQFl4QvrnBe0LxwwnUoGBJE3OGsphuFBW2jh9ZjO9QVgq34qxwjcX4Xvuy9-fzqbdS1a4gcGfEyKp3wQvsEPaGzdLaQGabkw3RaxOhtIn2BI1WUKNHHMSolnJMSSQPSa5_FyT3YqOoKH0CYuiT2QngKIKTUNi9yXaS5tN6lXqUSAxj1T824jsucW2pMTZPTZMq0KjWkUtOo1JwG8GI9Z9YyefxV-iWDYS3JLNzNhXr-zXRGbQjn6IuU-7Wk0jmK1CylnwRyH1MWlrsAthhKpi1pXfsSs6u04MYAeRbA80aCvQktwNmuKILUwLxcA8nNgSR5ATcc7uFqOi-0MJQuJoLyYZEE8HQ9zDP5ZF2F9THLUIKuc0qcA7jfonu9aIpwuHwoD0APcD_QynCkmnxvOMop7oy1UAFs9-j_-bP-rPWH_ya-BVf3X--ZD-_G7x_BNdHYj4pEsgkby_kxPobL7mQ5WcyfNE7hB_cFZAg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+the+intestinal+microbiome+and+microbial-derived+metabolites+in+immune+checkpoint+blockade+immunotherapy+of+cancer&rft.jtitle=Genome+medicine&rft.au=Eiko+Hayase&rft.au=Robert+R.+Jenq&rft.date=2021-06-23&rft.pub=BMC&rft.eissn=1756-994X&rft.volume=13&rft.issue=1&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1186%2Fs13073-021-00923-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ea8edb5674854cc283a7161dad05859c |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-994X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-994X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-994X&client=summon |